TABLE 2

Effect on islet allograft survival of adoptive transfer of thymic self-DCs isolated from syngeneic recipients of intrathymic inoculation of alloMHC P5

GroupImmunosuppression (intraperitoneal ALS on day −7)Inoculation of in vivo P5-primed thymic-self-DCs (route)Islet donorGraft survival time (days)MST ± SD (days)
I300 μg P5 (i.t.)WF47, 50, 66, >200 (3 animals)>200
II0.5 ml300 μg P5 (i.t.)WF>200 (8 animals)>200
III0.5 ml300 μg P5 (i.t.)BN14, 15, 16, 18, 1816.2 ± 1.8
IV5 × 106 P5-primed thymic DC (i.v.)WF26, 27, 28, 2927.5 ± 1.2
V0.5 ml5 × 106 P5-primed thymic DC (i.v.)WF72, >200 (3 animals)>200
VI0.5 ml5 × 106 P5-primed thymic DC (i.v.)BN11, 11, 14, 1512.8 ± 1.8
  • ACI recipients were pretreated with intrathymic (i.t.) inoculation of 300-μg P5 with or without ALS immunosuppression or pretreated with intravenous (i.v.) injection of in vivo 5 × 106 P5-primed thymic DC isolated from the thymus of ACI rats 2 days after i.t. injection of 300-μg P5. Each animal was transplanted with intraportal injection of 1,200–1,500 islets from WF (donor) or BN (third party) rats.